Total
0
Shares
Rhinomed (ASX:RNO) - CEO Michael Johnson
CEO Michael Johnson
Source: Rhinomed
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Rhinomed (RNO) receives a purchase order from the NSW Government for its COVID-19 testing nasal swab, Rhinoswab
  • NSW Health Pathology has ordered one million Rhinoswabs as part of its program to support testing capability
  • The company has started delivering and is expected the whole order to be completed over the coming weeks
  • On the market, Rhinomed is up 52.5 per cent, trading at 30.5 cents per share at 12:27 pm AEST

Rhinomed (RNO) has received a purchase order from the NSW Government for its COVID-19 testing nasal swab, Rhinoswab.

NSW Health Pathology has ordered one million Rhinoswabs as part of its program to support testing capability.

The company has started delivering and is expected the whole order to be completed over the coming weeks.

RNO is now scaling up its manufacturing facilities to respond to growing domestic and international demand for this innovative technology.

The Rhinoswab technology improves the sample collection process, and is substantially more comfortable and easier to use than the standard nasal swab.

Importantly, the technology can speed up the sample collection process and significantly reduce queues and waiting times.

CEO Michael Johnson is thrilled with the order.

“The Rhinoswab can make a meaningful impact on the SARS-CoV-2 testing process and enable more people to be tested quickly and easil,” Mr Johnson said.

“With approximately two billion SARS-CoV-2 tests having been carried out globally over the past 18 months (close to 26 million* in Australia alone), there is a major opportunity for Rhinoswab to radically improve the testing process, clinical outcomes and user experience.”

On the market, Rhinomed is up 52.5 per cent, trading at 30.5 cents per share at 12:27 pm AEST.

RNO by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.